Trials / Unknown
UnknownNCT02489006
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study that will look at the effects and how useful investigational drug olaparib is as a neoadjuvant treatment (treatment given as to shrink a tumor before the main treatment) prior to surgery in patients with recurrent ovarian, primary peritoneal or fallopian tube cancer.
Detailed description
Olaparib belongs to a class of anti-cancer agents known as poly ADP-ribose polymerase (PARP) inhibitors. Olaparib is a new type of drug for ovarian cancer. Laboratory tests show that it may help slow the growth of ovarian cancer. Olaparib works by blocking the PARP protein. PARP is an important protein which tries to fix damaged deoxyribonucleic acid (DNA, molecules that contain important instructions for the development of cells). Many cancers are thought to develop from damaged DNA. Research has shown that PARP inhibitors stop the PARP protein from working, and that sometimes that can cause cancer cells to stop growing or die.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaparib | |
| DRUG | Platinum-based Chemotherapy | Chosen by the study doctor, per standard of care. |
Timeline
- Start date
- 2016-07-19
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2015-07-02
- Last updated
- 2024-01-17
Locations
9 sites across 4 countries: Canada, New Zealand, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02489006. Inclusion in this directory is not an endorsement.